Clinical Trial Update: Hematologic Response of Epoetin Alfa (PROCRIT) Versus Darbepoetin Alfa (ARANESP) in Chemotherapy Induced Anemia [Phase 4]

View source ↗

Summary

This Phase 4 trial compares hematologic response between epoetin alfa (PROCRIT) and darbepoetin alfa (ARANESP) in chemotherapy-induced anemia and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Anemia

Drugs mentioned

• ARANESP (DARBEPOETIN ALFA)
• PROCRIT (ERYTHROPOIETIN)

Snippet

Sponsor: Ortho Biotech Products, L.P. | Conditions: Anemia, Chemotherapy | Phase 4 | Status: COMPLETED